Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Development of hyperdiploidy starts at an early age and takes a decade to complete

Mehmet K. Samur, Anil Aktas Samur, Parth Shah, Joseph Park, Mariateresa Fulciniti, Masood A Shammas, Jill Corre, Kenneth C. Anderson, Giovanni Parmigiani, Hervé Avet-Loiseau, Nikhil C. Munshi

Blood blood.2024025250.

https://doi.org/10.1182/blood.2024025250

Published: 2024

Includes: Supplemental data

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma

Subodh Kumar, Srikanth Talluri, Jiangning Zhao, Chengcheng Liao, Lakshmi B. Potluri, Leutz Buon, Shidai Mu, Jialan Shi, Chandraditya Chakraborty, Yu-Tzu Tai, Mehmet K. Samur, Nikhil C. Munshi, Masood A. Shammas

Blood (2024) 143 (11): 996–1005.

https://doi.org/10.1182/blood.2023021225

Published: 2024

Includes: Supplemental data

Journal Articles

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Na Liu, Vanessa Favasuli, Marcello Turi, Pietro Folino, Mariateresa Fulciniti, Annamaria Gulla, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 640.

https://doi.org/10.1182/blood-2023-185523

Published: 2023

Journal Articles

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Mariateresa Fulciniti, Shuhui Deng, Sanika Dereibal, Vera Joy Weiler, Madhumouli Chatterjee, Jessica Ng Fong, Chandraditya Chakraborty, Rao Prabhala, Masood A. Shammas, Anil Aktas-Samur, Mehmet K. Samur, Annamaria Gulla, Kenneth C. Anderson, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2023-187374

Published: 2023

Journal Articles

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Raphael E Szalat, Srikanth Talluri, Charlotte M Royer, Sherry Wong, Gareth Morgan, Vaishali Sanchorawala, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 3416.

https://doi.org/10.1182/blood-2023-178730

Published: 2023

Journal Articles

Transcriptional Co-Activator P300 Promotes Extra-Medullary Disease Formation and Myeloma Disease Progression

Rajib Shome, Srikanth Talluri, Tsuyoshi Fukushima, Mehmet K. Samur, Rie Nakamoto-Matsubara, Cristina Panaroni, Keertik Fulzele, Kiyosumi Ochi, Ryan Seongmin Han, Farah Rexha, David Scadden, Nikhil C Munshi, Noopur S. Raje

Blood (2023) 142 (Supplement 1): 1939.

https://doi.org/10.1182/blood-2023-189362

Published: 2023

Journal Articles

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Kris Richardson, Nickolas Tsakmaklis, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Zachary R Hunter, Steven P Treon

Blood (2023) 142 (Supplement 1): 1946.

https://doi.org/10.1182/blood-2023-190631

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Zachary R Hunter, Nickolas Tsakmaklis, Kris Richardson, Maria Luisa Guerrera, Amanda Kofides, Xia Liu, Shirong Liu, Catherine A. Flynn, Kirsten Meid, Christopher J Patterson, Mariateresa Fulciniti, Mehmet K. Samur, Kenneth C. Anderson, Nikhil C Munshi, Shayna R Sarosiek, Jorge J. Castillo, Ari M Melnick, Steven P Treon

Blood (2023) 142 (Supplement 1): 755.

https://doi.org/10.1182/blood-2023-190825

Published: 2023

Journal Articles

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Blood (2023) 142 (Supplement 1): 756.

https://doi.org/10.1182/blood-2023-190685

Published: 2023

Journal Articles

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Blood (2023) 142 (Supplement 1): 7248.

https://doi.org/10.1182/blood-2023-184710

Published: 2023

Journal Articles

Multi-Level Control of Myeloma Cell Proliferation and Genomic Instability By the PDZ Binding Kinase (PBK)

Lai Shi, Srikanth Talluri, Subodh Kumar, Jiangning Zhao, Chengcheng Liao, Leutz Buon, DeYao Shi, Shidai Mu, Lakshmi B. Potluri, Chandraditya Chakraborty, Jialan Shi, Mehmet K. Samur, Masood A. Shammas, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 6606.

https://doi.org/10.1182/blood-2023-188922

Published: 2023

Journal Articles

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

Ting Du, Yan Song, Arghya Ray, Xueping Wan, Yao Yao, Mehmet K. Samur, Chen Shen, Johany Penailillo, Tomasz Sewastianik, Yu-Tzu Tai, Mariateresa Fulciniti, Nikhil C. Munshi, Hao Wu, Ruben D. Carrasco, Dharminder Chauhan, Kenneth C. Anderson

Blood (2023) 141 (21): 2599–2614.

https://doi.org/10.1182/blood.2022017897

Published: 2023

Includes: Supplemental data

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Tengteng Yu, Mu Hao, Hailin Chen, Kenneth Wen, Tingjian Wang, Thomas C.M Smits, Mehmet K. Samur, Eugenio Morelli, Lijie Xing, Liang Lin, Jun Qi, Gang An, Nikhil C Munshi, Yu-Tzu Tai, Lugui Qiu, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 854–855.

https://doi.org/10.1182/blood-2022-159137

Published: 2022

Journal Articles

In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

Anil Aktas-Samur, Jill Corre, Laure Buisson, Mariateresa Fulciniti, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi, Herve Avet-Loiseau

Blood (2022) 140 (Supplement 1): 4362–4363.

https://doi.org/10.1182/blood-2022-168943

Published: 2022

Journal Articles

BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells

Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 596–597.

https://doi.org/10.1182/blood-2022-162445

Published: 2022

Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Jiye Liu, Lijie Xing, Teru Hideshima, Keiji Kurata, Mehmet K. Samur, Eugenio Morelli, Kenneth Wen, Nikhil C Munshi, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 360–361.

https://doi.org/10.1182/blood-2022-164901

Published: 2022

Journal Articles

Exonuclease 1 Drives Growth and Genomic Instability in Multiple Myeloma through Interaction with CAD, a Key Protein Involved in De Novo Pyrimidine Biosynthesis

Shidai Mu, Srikanth Talluri, Jiangning Zhao, Lai Shi, Hannah Seah, Lakshmi B. Potluri, Jialan Shi, Mehmet K. Samur, Masood A. Shammas, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 4196–4197.

https://doi.org/10.1182/blood-2022-169978

Published: 2022

NARROW

Development of hyperdiploidy starts at an early age and takes a decade to complete

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Venetoclax Resistance Results in Broad Resistance to Majority of Anti-MM Agents Due to the Suppression of Apoptosis but Can be Overcome By BCMA-Targeted Immunotherapy

Composition and Dynamic Evolution of the Bone Marrow Microenvironment in AL Amyloidosis during Daratumumab Based Therapy

Transcriptional Co-Activator P300 Promotes Extra-Medullary Disease Formation and Myeloma Disease Progression

Novel Isoforms Identified By Isoseq Analysis Drive Expression Differences in Key Genes That Delineate the Subtypes of Waldenstrom's Macroglobulinemia

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Changes in Methylation and Chromatin Accessibility Underlie Subtype Classification and Disease Evolution in Waldenström's Macroglobulinemia

Atypical Stem Cell, Pre-B-Cell, T-Cell and Myeloid Gene Expression Characterizes Early Waldenstrom's Macroglobulinemia Clones Which Diminishes with Advancing Disease and Has Therapeutic Implications

Heterogeneity in Access and Toxicity Management of Commercially Available BCMA-Directed CAR-T and Bispecific T-Cell Engager Therapy Among the International Myeloma Community

Multi-Level Control of Myeloma Cell Proliferation and Genomic Instability By the PDZ Binding Kinase (PBK)

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

In Multiple Myeloma Patients without Known Cytogenetic Risk Features, Genomic Features Contribute to Early Death Risk at Diagnosis

BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells

Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Exonuclease 1 Drives Growth and Genomic Instability in Multiple Myeloma through Interaction with CAD, a Key Protein Involved in De Novo Pyrimidine Biosynthesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only